​For non-transplant eligible patients, initial treatment may be stopped after attainment and maintenance of the deepest response for at least four months. Treatment should be changed to secondary regimens if progressive disease develops during primary treatment. If treatment has been stopped because of an adequate response it should be resumed on the first objective evidence of progressive disease.​